<DOC>
	<DOCNO>NCT00816686</DOCNO>
	<brief_summary>This first human study AGS-16M18 give every week subject advance renal cell cancer . AGS-16M18 administer 60 minute IV infusion consecutive day disease worsens .</brief_summary>
	<brief_title>A Phase 1 Study Safety Pharmacokinetics AGS-16M18 Subjects With Advanced Renal Cell Cancer</brief_title>
	<detailed_description>Subjects enrol sequentially 5 plan dose cohort accord standard , dose escalation study design . A disease assessment perform study week 5 ( +/- 3 day ) investigator . The assessment base change clinical symptom , radiographic image . Subjects without evidence disease progression may receive AGS-16M18 extended therapy dose schedule assign cohort disease progression intolerability AGS-16M18 . Disease assessment perform every 8 week extended period . A safety follow-up visit occur 4 week last infusion AGS-16M18 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>Histologic cytologic diagnosis ( recent remote ) metastatic renal cell carcinoma ( include papillary , clear cell , exclude transitional cell type ) amendable cure surgery mean , must fail least one prior systemic therapy , include limited treatment sunitinib , temsirolimus sorafenib Evaluable/Measureable disease accord Response Criteria Solid tumor Eastern Cooperative Group performance status 01 Therapeutic anticoagulation ( PT , and/or INR , PTT ) permit , clinically stable &gt; /= 3 month initiation Past present document central nervous system ( CNS ) tumor CNS metastasis Use investigational drug ( include market drug approve indication ) within 4 week prior screen 5 halflives prior investigational drug ( whichever longer ) History thromboembolic event bleed disorder &lt; /= 3 month ( e.g. , DVT PE ) Major Surgery ( require general anesthesia ) within 4 week study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>clinical trial , phase 1</keyword>
	<keyword>carcinoma , advance renal cell</keyword>
	<keyword>kidney</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
	<keyword>AGS-16M18</keyword>
</DOC>